DE60214533T2 - Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen - Google Patents

Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen Download PDF

Info

Publication number
DE60214533T2
DE60214533T2 DE60214533T DE60214533T DE60214533T2 DE 60214533 T2 DE60214533 T2 DE 60214533T2 DE 60214533 T DE60214533 T DE 60214533T DE 60214533 T DE60214533 T DE 60214533T DE 60214533 T2 DE60214533 T2 DE 60214533T2
Authority
DE
Germany
Prior art keywords
methyl
group
hydrogen
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60214533T
Other languages
German (de)
English (en)
Other versions
DE60214533D1 (de
Inventor
Bernard Bourrie
Pierre Casellas
Jean-Marie Derocq
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE60214533D1 publication Critical patent/DE60214533D1/de
Application granted granted Critical
Publication of DE60214533T2 publication Critical patent/DE60214533T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60214533T 2001-04-27 2002-04-26 Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen Expired - Lifetime DE60214533T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0105843 2001-04-27
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone
PCT/FR2002/001450 WO2002087575A1 (fr) 2001-04-27 2002-04-26 Associations pharmaceutiques a base de derives de pyridoindolone et d'agents anticancereux

Publications (2)

Publication Number Publication Date
DE60214533D1 DE60214533D1 (de) 2006-10-19
DE60214533T2 true DE60214533T2 (de) 2007-06-21

Family

ID=8862882

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60214533T Expired - Lifetime DE60214533T2 (de) 2001-04-27 2002-04-26 Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
DE60208365T Expired - Lifetime DE60208365T2 (de) 2001-04-27 2002-04-26 Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60208365T Expired - Lifetime DE60208365T2 (de) 2001-04-27 2002-04-26 Verwendung von pyridoindolonderivaten zur herstellung von antikrebsmitteln

Country Status (33)

Country Link
US (3) US6967203B2 (enExample)
EP (2) EP1385512B1 (enExample)
JP (2) JP2004531538A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE314070T1 (enExample)
BG (2) BG108260A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2444334A1 (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ295224B6 (enExample)
DE (2) DE60214533T2 (enExample)
DK (2) DK1385513T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2271264T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400745A2 (enExample)
IL (4) IL158266A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034785L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385512E (enExample)
RS (2) RS50791B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087575A1 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) * 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
JPH10501686A (ja) * 1994-04-13 1998-02-17 ザ ロックフェラー ユニヴァーシティ 神経系の細胞へのｄｎａのａａｖ仲介送達
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
CA2326319A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CZ20032909A3 (en) 2004-06-16
YU83903A (sh) 2006-08-17
CA2444334A1 (fr) 2002-11-07
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
ES2271264T3 (es) 2007-04-16
WO2002087574A3 (fr) 2003-02-13
EE200300465A (et) 2003-12-15
US20050272760A1 (en) 2005-12-08
IL158266A (en) 2009-09-01
RU2292888C2 (ru) 2007-02-10
NZ528671A (en) 2004-06-25
US7160895B2 (en) 2007-01-09
EA005930B1 (ru) 2005-08-25
NO20034787L (no) 2003-12-23
DE60214533D1 (de) 2006-10-19
EA200301062A1 (ru) 2004-04-29
IL158312A (en) 2009-09-01
PT1385513E (pt) 2007-01-31
CZ295224B6 (cs) 2005-06-15
DE60208365T2 (de) 2006-09-07
YU83403A (sh) 2006-08-17
JP2004531538A (ja) 2004-10-14
AR034313A1 (es) 2004-02-18
SK13242003A3 (sk) 2004-03-02
HK1060066A1 (en) 2004-07-30
IS6984A (is) 2003-10-09
NO20034787D0 (no) 2003-10-24
MXPA03009639A (es) 2004-06-30
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
KR20040015138A (ko) 2004-02-18
DK1385512T3 (da) 2006-05-22
EP1385513B1 (fr) 2006-09-06
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
CN1505511A (zh) 2004-06-16
DK1385513T3 (da) 2007-01-15
PL366910A1 (en) 2005-02-07
CA2443012C (fr) 2009-07-28
HK1059895A1 (en) 2004-07-23
CZ20032910A3 (en) 2004-07-14
NO20034785D0 (no) 2003-10-24
CZ299465B6 (cs) 2008-08-06
KR100847413B1 (ko) 2008-07-18
CA2443012A1 (en) 2002-11-07
UA74876C2 (en) 2006-02-15
HUP0400745A2 (hu) 2004-08-30
RS50791B (sr) 2010-08-31
EP1385512B1 (fr) 2005-12-28
DE60208365D1 (de) 2006-02-02
IL158266A0 (en) 2004-05-12
PT1385512E (pt) 2006-05-31
FR2823975A1 (fr) 2002-10-31
RU2003130376A (ru) 2005-04-10
PL366916A1 (en) 2005-02-07
CN1240382C (zh) 2006-02-08
EE200300466A (et) 2003-12-15
ZA200307785B (en) 2004-10-06
BR0209138A (pt) 2004-06-08
US6967203B2 (en) 2005-11-22
US7524857B2 (en) 2009-04-28
JP2004528343A (ja) 2004-09-16
IS2441B (is) 2008-11-15
ATE314070T1 (de) 2006-01-15
IL158312A0 (en) 2004-05-12
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
EP1385513A1 (fr) 2004-02-04
RS50790B (sr) 2010-08-31
SK13252003A3 (sk) 2004-03-02
WO2002087575A1 (fr) 2002-11-07
US20040122027A1 (en) 2004-06-24
CN1505510A (zh) 2004-06-16
US20040122036A1 (en) 2004-06-24
BG108260A (bg) 2004-12-30
CY1105813T1 (el) 2011-02-02
HUP0400744A2 (hu) 2004-06-28
ES2254683T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
DE69121827T2 (de) Verwendung von Angiotensin-II-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Hyperuricemie
EP2443125B1 (en) Camptothecin derivatives
JP2004531549A5 (enExample)
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
EP3525886B1 (en) Compositions comprising a metal source, dithiocarbamate and cyclodextrin
EP0236951A2 (de) Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen
DE60214533T2 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
DE60212710T2 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
DE69103908T2 (de) Verbessertes behandlungsverfahren für krebs.
EP1984005B1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen
WO2002074304A2 (de) Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum
EP3028696A1 (en) Agent for alleviating side effects in cancer chemotherapy
HRP20040241A2 (en) Use of 4-pyridylphalazines for cancer treatment
AT501819B1 (de) Verwendung von gallium(iii)-komplexen zur behandlung von tumorerkrankungen der leber
HK1060066B (en) Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
AT501262B1 (de) Verwendung von gallium(iii)-komplexen zur behandlung von tumoren des urothelialtraktes
DE554032T1 (de) Schwefel enthaltende bizyklische Verbindungen zur Behandlung von durch Immunsystemstörungen verursachte Krankheiten.
JPWO2001012198A1 (ja) 心筋梗塞治療薬

Legal Events

Date Code Title Description
8364 No opposition during term of opposition